Review Course
Iain McInnes, PhD, FRCP
Professor of Medicine and Rheumatology
University of Glasgow
Glasgow, United Kingdom
Disclosure(s): AbbVie: Consultant (Ongoing); Amgen: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Causeway Therapeutics: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Compugen: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Dextera: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Moonlake: Consultant (Ongoing); NHS GGC: Officer or Board Member (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Sanofi: Consultant (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing); Versus Arthritis: Trustee Status (Ongoing)